LYSEMED
The computed 12-month bankruptcy probability of LYSEMED is 4.8% (elevated). The 2024 annual accounts show equity of €558k and a net result of €340k. The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €558k |
| Net result | €340k |
| Active | 3 yrs |
| Board | 1 |
Exceptional profile, strong across almost every axis.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | €483k |
| Net profit | €340k |
| Cash flow | €368k |
| Staff costs | - |
| Income taxes | €112k |
| Dividends | - |
| Total assets | €738k |
| Equity | €558k |
| Debt | €180k |
| of which ≤ 1y | €131k |
| of which > 1y | €49k |
| Working capital | €517k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 4.94 |
| Quick ratio | 4.94 |
| Working capital ratio | 70.0% |
| Solvency | 75.6% |
| Debt / equity | 0.32 |
| Long-term debt ratio | 0.09 |
| Interest coverage | 155.97 |
| Gross margin | - |
| Net margin | - |
| ROA | 46.0% |
| ROE | 60.9% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €738k |
| Fixed assets | 21/28 | €91k |
| Tangible fixed assets | 22/27 | €91k |
| Current assets | 29/58 | €648k |
| Amounts receivable within one year | 40/41 | €270k |
| Cash & bank | 54/58 | €242k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €738k |
| Equity | 10/15 | €558k |
| Contributions / capital | 10/11 | €3k |
| Accumulated profits (losses) | 14 | €555k |
| Amounts payable | 17/49 | €180k |
| Amounts payable after one year | 17 | €49k |
| Amounts payable within one year | 42/48 | €131k |
| Trade debts payable within one year | 44 | €630 |
| Income statement | ||
| Gross operating margin | 9900 | €484k |
| Operating result | 9901 | €455k |
| Financial income | 75 | €0 |
| Financial charges | 65 | €3k |
| Result before taxes | 9903 | €452k |
| Income taxes | 67/77 | €112k |
| Net result for the period | 9904 | €340k |
| Result to be appropriated | 9905 | €340k |
-
Current15-04-2024 → present
| NACE primary | - |
| Legal form | Private limited company(610) |
| Incorporation | 31-03-2023 |
| Status | Active |
| Postal code | 1000 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21332B0493/00H035 | Brussels | 4,164 m² | 1 · 649 m² | 18.7 m · 5 fl. |
| 21822R0232/00X007 | Brussels | 665 m² | 1 · 573 m² | 34.6 m · 9 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
18-02-2026 Registered office moved from Auderghem to Bruxelles
- Clos Albert Crommelynck 6, 1160 Auderghem → Avenue du Congo 16, 1000 Bruxelles
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Bruxelles",
"region": "Brussels",
"street": "Avenue du Congo",
"country": "BE",
"postcode": "1000",
"box_number": "22",
"street_number": "16"
},
"old_address": {
"city": "Auderghem",
"region": "Brussels",
"street": "Clos Albert Crommelynck",
"country": "BE",
"postcode": "1160",
"box_number": "2",
"street_number": "6"
},
"effective_date": "2025-11-01",
"evidence_quote": "L\u0027organe d\u0027administration d\u00E9cide de transf\u00E9rer le si\u00E8ge de la soci\u00E9t\u00E9 \u00E0 l\u0027adresse suivante \u00E0 dater du novembre 2025: Avenue du Congo 16 bte 22 -1000 Bruxelles"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0800.217.930",
"name_full": "LYSEMED",
"legal_form": "SRL"
}
}15-04-2024 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": true,
"seat_change": false,
"object_change": false,
"effective_date": "2024-04-03",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0800.217.930",
"name_full": "DOCTEUR SANAK",
"legal_form": "SRL"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}04-04-2023 Incorporation of a new SRL
Technical details
{
"kind": "oprichting",
"seat": "1160 Auderghem, Clos Albert Crommelynck 6 bte 2",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1993-10-02",
"name": "SANAK Nuri Serdal",
"niss": null,
"address": "1160 Auderghem, Clos Albert Crommelynck 6 bo\u00EEte 2"
},
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 3000,
"holder_person_name": "SANAK Nuri Serdal",
"is_subscriber_only": false,
"n_shares_subscribed": 30,
"amount_subscribed_eur": 3000,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 3000,
"subject_company": {
"kbo": "0800.217.930",
"name_full": "Docteur Sanak",
"legal_form": "SRL"
},
"initial_directors": [],
"incorporation_date": "2023-03-30",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | LYSEMED |